A black background with a black squareAI-generated content may be incorrect.

 

Lumenis Establishes Ophthalmology Advisory Board to Shape the Future of Dry Eye Management

Industry Leaders to Inform and Support Practice Adoption of Advanced Technologies

 

As dry eye care continues to shift toward interventional treatment, Lumenis has established its inaugural Ophthalmology Advisory Board. The board brings together leading clinicians whose clinical expertise and strategic counsel will help guide Lumenis’s continued innovation in the development of advanced technologies to address dry eye disease, ocular surface disease, and other ophthalmic applications.

 

The advisory board convened for the first time in Washington, D.C., where members discussed the broader shift toward interventional dry eye care to enhance patient outcomes, as well as the opportunities and challenges practices face in delivering these treatments consistently and effectively to patients.

 

“Lumenis is committed to advancing the standard of care by equipping ophthalmologists with technologies that elevate clinical outcomes and practice performance,” said Audrey Eberth, Vice President of Sales, U.S. Vision at Lumenis. “Through this distinguished group of physicians, we’re better able to understand the realities of ophthalmic practice and ensure our solutions are aligned with patient needs and how care is delivered. Their perspectives strengthen how we support physicians today while helping drive the next generation of technologies.”

Advisory board members include:

Neel Desai, MD, is a board-certified, fellowship-trained ophthalmologist at The Eye Institute of West Florida. A pioneer in interventional dry eye care, he has incorporated OptiLIGHT as a central component of his treatment protocol and co-authored a landmark randomized controlled trial demonstrating the efficacy of intense pulsed light for meibomian gland dysfunction.

Mina Massaro-Giordano, MD, serves as Director of the Dry Eye Service for the NYU Langone Eye Center. With more than 25 years dedicated to advancing understanding and treatment of dry eye, her research focuses on the disease’s neural and inflammatory components. She has led and participated in multiple clinical trials and authored more than 100 peer-reviewed publications.

Kendall Donaldson, MD, is the Rodgers Clark Endowed Chair in Ophthalmology and Professor of Clinical Ophthalmology at Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, where she also serves as Medical Director of the Plantation campus. A cornea specialist with more than 20 years of clinical and academic experience, she is a prolific national and international lecturer and author of numerous peer-reviewed publications.

Jai Parekh, MD, is a board-certified anterior segment surgeon and co-founder of EyeCare Consultants of NJ, with over 20 years specializing in ocular surface disease, dry eye, cornea, cataract, and glaucoma. He also serves as Chief of Cornea and External Diseases and Medical Director of the Research Institute at St. Joseph’s Health System, and as a Clinical Associate Professor at the Icahn School of Medicine at Mount Sinai.

Eric Gerschenbaum, MD, is an ophthalmologist at the Witlin Center for Advanced Eye Care in New Jersey. He is a published author, lecturer, and clinical instructor with over 20 years of experience in advanced cataract and refractive surgery.

 

For more information about Lumenis’s portfolio of advanced eye care technologies, visit Lumenis.com/vision/homepage.

 

### 

 

Media Contact

Carson Daniels

McDougall Communications for Lumenis

carson@mcdougallpr.com or +1.315.427.6394